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Summary
NCAM 180 isoform null neuromuscular junctions are
unable to effectively mobilize and exocytose synaptic
vesicles and thus exhibit periods of total transmis-
sion failure during high-frequency repetitive stimula-
tion. We have identified a highly conserved C-terminal
(KENESKA) domain on NCAM that is required to
maintain effective transmission and demonstrate that
it acts via a pathway involving MLCK and probably
myosin light chain (MLC) and myosin II. By perfecting
a method of introducing peptides into adult NMJs, we
tested the hypothesized role of proteins in this path-
way by competitive disruption of protein-protein in-
teractions. The effects of KENESKA and other pep-
tides on MLCK and MLC activation and on failures in
both wild-type and NCAM 180 null junctions sup-
ported this pathway, and serine phosphorylation of
KENESKA was critical. We propose that this pathway
is required to replenish synaptic vesicles utilized dur-
ing high levels of exocytosis by facilitating myosin-
driven delivery of synaptic vesicles to active zones or
their subsequent exocytosis.
Introduction
Adult mice that lack all three major isoforms of the neu-
ral cell adhesion molecule NCAM are unable to sustain
effective transmission with high-frequency repetitive
stimulation and exhibit both severe depression and to-
tal transmission failures. These mice also maintain an
immature vesicle cycling mechanism in their axons and
terminals (Polo-Parada et al., 2001). In contrast, mice
that lack only the 180 kDa isoform of NCAM appro-
priately downregulate the immature vesicle cycling
mechanism; however, transmission defects persist (Polo-
Parada et al., 2004). While NCAM 180 null neuromuscu-
lar junctions (NMJs) do not exhibit severe depression,
they do have periods of total transmission failures, with
stimulus rates as low as 50 Hz. In addition, vesicle exo-
cytosis is not selectively targeted to active zones ap-
posed to muscle, and other presynaptic proteins are
more diffusely localized, including the P/Q-type Ca2+
channels responsible for transmission at these NMJs
(Polo-Parada et al., 2004).
How might the absence of the 180 kDa isoform of
NCAM result in these severe defects in presynaptic
structure and function? NCAM participates in develop-
mental events, including axon growth and fasciculation,
cell migration, and synaptic maturation (Rutishauser*Correspondence: lynn.landmesser@case.eduand Landmesser, 1996; Kiss and Muller, 2001). Of the
three major alternatively spliced isoforms, the 120 kDa
isoform is GPI linked, whereas the 140 and 180 kDa
isoforms are transmembrane proteins, with cytoplas-
mic portions of different lengths (Cunningham et al.,
1987; Barbas et al., 1988). The extracellular portion of
NCAM, which is essentially identical for all isoforms,
can mediate homophilic interactions with itself or het-
erophilic interactions with other molecules (for reviews,
see Panicker et al., 2003; Hinsby et al., 2004). In addi-
tion to adhesion per se, NCAM has also been shown
to activate several intracellular signaling cascades (for
reviews, see Crossin and Krushel 2000; Panicker et al.,
2003; Hinsby et al., 2004). Upon clustering of NCAM
140, the tyrosine kinase fyn is activated, stimulating the
MAP-kinase pathway (Schmid et al., 1999; Kolkova et
al., 2001). Interaction of NCAM 140 with the FGF recep-
tor evokes a signaling cascade via phospholipase C
and DAG, which leads to the influx of Ca2+ (Safell et
al., 1997). Both of these signaling cascades enhance
neurite extension.
The recently described defects in transmission at
NCAM 180 null adult NMJs (Polo-Parada et al., 2004)
suggest that, rather than acting as a homophilic adhe-
sion molecule, the 180 isoform of NCAM may act via
signaling or direct protein-protein interactions to orga-
nize presynaptic release machinery that is required to
sustain effective transmission with repetitive stimula-
tion. This prompted us to undertake a bioinformatical
characterization of the intracellular domain of NCAM.
Multiple potential interaction sites were detected within
the cytosolic portion of NCAM, including a domain at
the extreme C terminus of both 140 and 180 kDa iso-
forms that resembles a class I PDZ binding motif. We
chose to focus our studies on this domain since such
motifs have been shown to mediate the formation of
macromolecular complexes both pre- and postsynapti-
cally that are required for effective synaptic transmis-
sion (Craven and Bredt, 1998; Kim and Sheng, 2004).
Furthermore, the conservation of this C terminus do-
main in NCAM homologs and orthologs across many
species suggested that it was mediating a critical
function.
To probe the function of this domain in transmission
at adult mouse NMJs, we adapted a commercially
available peptide carrier (see Experimental Procedures)
system to introduce the heptapeptide KENESKA, repre-
senting the C-terminal portion of this conserved do-
main, into adult NMJs. We then assessed the acute ef-
fect on functional transmission and demonstrate here
that the cyclical total transmission failures that occur in
180 null NMJs with repetitive stimulation are pheno-
copied by the introduction of this peptide and, further,
that serine phosphorylation of this domain is critical.
In addition, we show that myosin light chain kinase
(MLCK) is a probable target of the NCAM-mediated sig-
naling and/or protein interactions mediated by this do-
main. We speculate that sufficient MLCK activity fol-
lowing repetitive stimulation may be required to convey
and/or exocytose synaptic vesicles at sufficient rates to
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918maintain effective transmission, probably via myosin-
Pdriven vesicle movement or other cytoskeletal alter-
ations. t
s
mResults
a
NInability of NMJs Lacking All Isoforms or Only the
o180 kDa Isoform of NCAM to Sustain Transmission
fwith High-Frequency Repetitive Stimulation
vWild-type adult mouse NMJs are capable of sustaining
teffective transmission even when stimulated at fre-
quencies as high as 200 Hz (Figure 1A). This requires
extensive synaptic vesicle cycling, since each EPP is A
ocomposed of approximately 90–100 quanta or vesicles.
Mice lacking only the 180 kDa isoform of NCAM do not D
Sexhibit the severe depression previously observed in
the NCAM null NMJs (Polo-Parada et al., 2001), but do T
aexhibit cyclical periods of total transmission failures at
stimulation frequencies of 50 Hz and above (Figure 1A; gFigure 1. Transmission Defects in the NCAM 180 Isoform Null NMJ and the Domain Structures of the Three Major NCAM Isoforms
(A) Wild-type P30 mouse NMJs do not exhibit transmission failures when stimulated with high-frequency trains, whereas NMJs lacking the
180 isoform of NCAM exhibit bouts of complete transmission failures.
(B) Overall domain structure of the alternatively spliced isoforms of NCAM.
(C) The C-terminal domain, which is highly conserved across species (data shown for mouse, rat, Xenopus, salamander, and human) contains
a PDZ-like binding motif and a putative serine phosphorylation site and is present in both the 140 and 180 isoforms of NCAM.Polo-Parada et al., 2004).Our previous studies (Polo-Parada et al., 2001; Polo-
arada et al., 2004) suggested that NCAM might con-
ribute to effective high-frequency repetitive transmis-
ion by helping to organize the presynaptic molecular
achinery required to sustain such high-demand syn-
ptic vesicle cycling. Since this seemed likely to involve
CAM participating in intracellular signaling cascades
r perhaps in a scaffold with other molecules required
or high-frequency transmitter release and synaptic
esicle cycling, we carried out a bioinformatic charac-
erization of the intracellular domain of NCAM.
Bioinformatic Analysis of the Intracellular Domain
f NCAM Reveals a Highly Conserved C-Terminal
omain with a PDZ-like Binding Motif and a Putative
erine Phosphorylation Site
he amino acid sequence of NCAM is highly conserved
mong vertebrate species, as is the overall domain or-
anization (Figure 1B, top). While the 140 and 180 kDaisoforms share highly homologous transmembrane and
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additional 267 amino acid long alternatively spliced in-
sert (residue 810–1076) encoded by exon 18 (Cunning-
ham et al., 1987), and its sequence varies more be-
tween species. The cytoplasmic sequence of NCAM
has a high content of hydrophilic (50%), charged (21%),
and proline (14%) residues, the latter being observed in
many synaptic proteins (Kay et al., 2000). Few second-
ary structures, such as α-helix, β sheet, or random coil,
would be predicted within the cytoplasmic tail due to
the high content of proline and charged hydrophilic res-
idues. This implies that the cytoplasmic domain has an
extended, exposed structure that could provide multi-
ple protein interaction sites. Within the 180-specific
domain, we identified several sequences (871–893,
930–970) with high similarities to cytoskeleton binding
proteins. Indeed, a recent study has reported interac-
tions of the NCAM 180 isoform with β-actin, tropo-
myosin, and microtubule-associated protein MAP 1A
(Buttner et al., 2003). Such cytoskeletal interactions
might constrain the molecule within the synapse and
account for the punctate immunostaining of the NCAM
180 isoform at junctions (Polo-Parada et al., 2004).
The carboxy-terminal sequence of NCAM (ATQTKEN
ESKA) is conserved across diverse species (Figure 1B,
bottom), and the most C-terminal portion KENESKA re-
sembles a class I PDZ binding domain. PDZ domains
are found in numerous scaffolding/adaptor molecules
such as PSD-95 and Discs-large (Dg) (Kim and Sheng,
2004) where they mediate the clustering and localiza-
tion of interacting proteins at specific synaptic sites
(Craven and Bredt, 1998; Kim and Sheng, 2004). Fur-
thermore, it has been demonstrated that functions/
interactions of the PDZ domain are regulated via phos-
phorylation of the serine/threonine residues within the
sequence (Chung et al., 2004; Kim and Sheng, 2004).
The high degree of conservation of this PDZ domain
indicated its likely importance in NCAM’s function. It
further suggested that interactions between this do-
main and other molecules in the presynaptic terminal
might serve to target other molecules to specific sites,
bringing about the appropriate targeting of transmitter
release to precise active zones as well as facilitating
the delivery of synaptic vesicles to these zones; both
of these processes appear to be defective in the 180
isoform null NMJ (Polo-Parada et al., 2004).
Adaptation of a Peptide Carrier to Acutely Introduce
Peptides into Adult NMJs to Assess the Role of
Particular Molecular Domains on Specific
Aspects of Functional Transmission
The adult NMJ is a complex structure, consisting of
highly organized and aligned pre- and postsynaptic
macromolecular aggregates and includes the presyn-
aptic terminal, an extensive synaptic basal lamina, the
postsynaptic muscle cell with extensive junctional
folds, as well as specialized Schwann cells that cap the
nerve terminal. It arises through a complex series of
bidirectional developmental interactions (Sanes and
Lichtman, 1999). Junctions formed in culture, while
amenable to viral transfection and electroporation, do
not contain all the components of the adult in vivo NMJ.
Furthermore, while direct protein-protein interactions
can be detected by yeast two-hybrid assays, direct in-troduction of peptides that can block specific interac-
tions into the adult NMJ allow one to assess their
impact on multiple aspects of mature functional trans-
mission in a physiologically intact setting. In addition,
the introduction of phosphopeptides would allow one
to probe the importance of the phosphorylation state
of various proteins in mediating specific effects. We
therefore surveyed several methods based on the Tat
or antennapedia means of getting peptides into cells
(Kabouridis, 2003) and found that a commercially avail-
able product, Chariot (Active Motif, Carslbad, CA), al-
lowed us to effectively introduce peptides into adult
NMJs.
Following dissection of semitendinosus muscles from
adult wild-type P30–P40 mice, an extensive electro-
physiological characterization of functional transmis-
sion was carried out at physiological Ca2+ levels ac-
cording to previously described protocols (Polo-Parada
et al., 2004). This included an analysis of EPP ampli-
tude, MEPP frequency and amplitude, and the ability of
NMJs to sustain transmission when stimulated with 1 s
trains at frequencies of 10, 20, 50, 100, and 200 Hz. The
peptide carrier alone was then applied for 1 hr while
recording from a muscle fiber. Following washout of the
carrier from the bath, the functional analysis of trans-
mission was repeated. When the peptide carrier alone
was applied at several different concentrations, we
detected no changes in muscle resting potential or an
increase in MEPP frequency that might indicate a pre-
synaptic depolarization during the 1 hr application. Fol-
lowing washout of the carrier, we also detected no
changes in any parameter of transmission compared to
either precarrier measurements or data from other wild-
type junctions (Figure 2A). There were no alterations in
the ability of the junction to sustain transmission when
stimulated with 50, 100, and 200 Hz 0.5–1 s trains dur-
ing the period tested (several hours) (Figure 2B). We
therefore combined the carrier with specific peptides,
according to the manufacturer’s instructions, and ap-
plied these to adult, acutely dissected NMJs for 1 hr,
determining their effects on transmission after washout
of carrier/peptide from the bath.
Introduction of the NCAM KENESKA Peptide into
Wild-Type NMJs Results in Transmission Failures
at High Stimulation Rates and Its Effectiveness
Is Modulated by Serine Phosphorylation
When the KENESKA peptide with carrier was intro-
duced into P30 wild-type NMJs using a bath concentra-
tion of 3 M for 1 hr and then washed out, electrophys-
iological analysis revealed no changes in quantal
content, MEPP frequency or size, or depression in re-
sponse to trains of stimuli (Figure 3A). However, when
the junctions were stimulated with repetitive stimula-
tion, transmission failures became apparent at 100 Hz
and increased at 200 Hz (Figures 3B and 3C, left pan-
els). When the concentration of the peptide was re-
duced 10-fold to 0.3 M, there were no transmission
failures, although some depression was apparent. For
each concentration, the number of failures or lack
thereof per 100 Hz train remained constant over several
hours (0.3 g, no failures; 3 g, 38 ± 5 failures; 300 g,
42 ± 7 failures; n = 8). These observations suggest that
the experiments presented in this study were carried
Neuron
920Figure 2. The Peptide Carrier Chariot Does
Not Produce Any Alterations in Transmission
at Wild-Type NMJs
(A) Exposure of P30 wild-type NMJs to Char-
iot alone for 30 min at three different concen-
trations had no effect on the quantal
content, MEPP frequency or amplitude, or
depression (expressed as the ratio of the
mean EPP amplitude of the first five to the
last five stimuli in a 1 s train).
(B) Introduction of Chariot alone also did not
result in any transmission failures at any
stimulation frequency, including 200 Hz, as
shown by traces of EPPs recorded in 2 mM
Ca2+ solution.
Quantification of data is expressed as the
mean ± SEM.out at concentrations in an appropriate part of the e
pdose-response curve (3 g for KENESKA) and that they
were therefore likely to be in the physiological range. t
tThe fact that such failures were only found at high stim-
ulus repetition rates but that all transmission parame- t
tters were normal to single stimuli showed that the over-
all health of the junctions was maintained and that t
mbasic exo- and endocytosis of vesicles was occurring
normally. As in the 180 null NMJs, defects only became l
napparent when junctions were challenged at high stim-
ulus repetition rates. Previously we found that introduc-
ition of the larger NCAM-derived ATQTKENESKA pep-
tide produced similar results as the KENESKA peptide c
t(data not shown).
The KENESKA domain has a putative serine phos- m
tphorylation site, although the kinases that might phos-
phorylate this site in vivo are unknown. To assess t
vwhether the phosphorylation of this site affected the
ability of the peptide to alter high-frequency transmis- m
asion, a peptide in which this serine had been phosphor-
ylated was introduced into wild-type junctions. As N
Kshown in Figures 3B and 3C (middle panels), the phos-
phorylated peptide produced a larger number of fail- s
mures, and these were more cyclic and occurred at lower
stimulus repetition rates than when the nonphosphory- (
tlated peptide was introduced. Overall, this phenotype
more closely resembled the phenotype in the 180 null t
lNMJ (compare Figures 3B and 3C, middle panels, to
Figure 1A). Replacement of the serine with an aspar- o
state, which should mimic phosphorylation of this site,
produced a similar amount of transmission failures (Fig- c
Hure 3B, right panel) as did the phosphorylated KEN
ESKA peptide. However, when the serine was replaced u
mby a glycine (KENEGKA), which is unable to be phos-
phorylated, there was no effect on transmission even t
cat 200 Hz (Figure 3C, right panel). This result also
served as a control for nonspecific effects of the intro- t
pduced peptide. In addition, introduction of a scrambled
peptide, CSNKATAETKQE, also was without effect v
2(data not shown).
Taken together the data strongly suggest a specific i
effect of the KENESKA domain on NCAM in sustainingffective high-frequency transmission and that serine
hosphorylation is critical. None of the introduced pep-
ides had any effects on basic transmission parameters
o single stimuli (Figure 3A). We propose that introduc-
ion of the exogenous KENESKA peptide into the junc-
ion interferes with the normal function/protein interac-
ions of the KENESKA domain on NCAM and thus
imics the transmission defects when this domain is
acking in either the NCAM null or 180 isoform-specific
ull NMJ.
The unusual total transmission failures could occur
f there were intermittent branch point failures in the
onduction of action potentials with resultant failure of
he presynaptic terminals to be depolarized. Since
ouse NMJs are not actively invaded by the action po-
ential but electrotonically depolarized by currents from
he last node or hemi-node, it is possible to record the
arious currents, including that of Ca2+ influx in the ter-
inal, by extracellular epineural recordings (Brigant
nd Mallart, 1982). We have previously found that in
CAM 180 null NMJs, there were no alterations in Na+,
+, or Ca2+ currents with high-frequency repetitive
timulation that would indicate failures of the nerve ter-
inal to be depolarized or a reduction in Ca2+ influx
Polo-Parada et al., 2004). To exclude the possibility
hat introduction of the KENESKA peptide produced
ransmission failures by affecting nerve terminal depo-
arization or Ca2+ influx, we repeated these recordings
n KENESKA-treated wild-type NMJs. Following the
timulus artifact, a fast sodium and slower potassium
urrent were recorded (Figure 3D, arrows). During a 100
z train, during which multiple total transmission fail-
res were always detected in the KENESKA-treated ter-
inal (Figures 3B and 3C), there were no alterations in
hese currents (Figure 3F). When the Ca2+-activated K+
urrent was blocked with 3,4-diaminopyridine, a peak
hat represents the Ca2+ current and which was com-
letely blocked by cadmium (data not shown) was re-
ealed (Figure 3E, arrow; see also Polo-Parada et al.,
004, Figure 5). Although there were slight fluctuations
n the size of this current during a 100 Hz train, there
were no large reductions (Figure 3G) that could account
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(A) Introduction of KENESKA, phospho-KENESKA, or the control KENEGKA via the Chariot peptide carrier into wild-type NMJs did not alter
quantal content, MEPP frequency, MEPP amplitude, or depression (expressed as the ratio of the mean EPP amplitude of the first five to the
last five stimuli in a 1 s train) compared to controls (white bars).
(B) However, failures at 100 Hz stimulation were produced by KENESKA and to a greater extent by phospho-KENESKA and KENEDKA, which
mimics phosphorylation of serine at this site. Bar graphs of the number of failures produced by KENESKA (left bar graph), phospho-KENESKA
(middle bar graph), and KENEDKA (right bar graph) at different stimulation frequencies. No failures were produced by the control KENEGKA
peptide at any frequency.
(C) Example traces of EPPs in response to 10, 20, 50, 100, and 200 Hz stimulation following introduction of KENESKA (left panel), phospho-
KENESKA (middle panel), and KENEGKA (right panel).
(D–G) Extracellular epineural recordings of the Na+, K+, and Ca2+ currents from wild-type NMJs treated with the KENESKA peptide. (D) The
response to a single stimulus reveals a fast Na+ current and a slower K+ current (arrows) following the stimulus artifact. When a 100 Hz train
was applied (F), there were no reductions in these currents that would indicate a failure of the nerve terminal to be depolarized. (E) Treatment
with 100 M 3,4-diaminopyridine to block Ca2+-activated K+ current revealed a slower peak that was completely blocked by 200 M cadmium
(data not shown) and which thus represents the Ca2+ influx into the terminal. (G) There was no reduction or complete block of this current
during a 100 Hz train that would indicate a failure of Ca2+ influx as underlying the total transmission failures observed as in Figure 3C,
left panel.
Quantification of data is expressed as the mean ± SEM.for the total transmission failures produced by the KEN
ESKA peptide. Thus, as with the failures at the NCAM
180 null NMJs, we propose that these failures are pro-
duced by a mechanism downstream of nerve terminal
depolarization and Ca2+ influx.
The KENESKA Domain of NCAM May Mediate Its
Effect on Transmission through Downstream
Activation of Myosin Light Chain Kinase
We previously observed that transmission failures sim-
ilar to those observed in NCAM null or 180 isoform nullNMJs could be produced by the MLCK inhibitor ML-9
at concentrations considered specific for MLCK (Polo-
Parada et al., 2001; Polo-Parada et al., 2004). Previous
studies have shown that inhibiting the action of MLCK
by drugs such as ML-9 (Ryan, 1999) or specific block-
ing peptides (Mochida et al., 1994; Mochida, 1995)
interferes with normal neural transmission. However,
because of potential lack of specificity of ML-9, we
used the peptide carrier method to introduce an inhibi-
tory peptide known to block MLCK (Kemp et al., 1987).
Five major alternatively spliced isoforms of MLCK are
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smuscle isoform” and a “nonmuscle isoform.” The
smooth muscle isoform has been studied extensively m
csince it is a major regulator of smooth muscle con-
traction. The inhibitory peptides mimic the binding of p
aan autoinhibitory domain of MLCK to prevent MLCK ac-
tivation. Following stimulation of neurons or muscle (
there is a Ca2+/calmodulin activation of MLCK, resulting
in a conformational change, allowing MLCK to phos- w
uphorylate myosin light chain (Kamm and Stull, 2001).
We found that a MLCK inhibitory peptide (see Experi- w
tmental Procedures) caused periods of transmission
failures that closely resembled those of the 180 null M
oNMJ. Transmission failures were common even at 50
Hz and became even more frequent at 100 Hz (Figures s
m4A and 4B). The MLCK inhibitory peptide had no effect
on quantal content, MEPP frequency or amplitude, or f
adepression (Figure 4C). Thus, as with the KENESKA
peptide, failures in transmission were only detected o
awith repetitive stimulation.
These results suggest that transmission may be im- b
tpaired at junctions that lack all or only the 180 isoform
of NCAM, because MLCK is not appropriately acti- t
svated. If true, one would predict that constitutively acti-
vating MLCK would rescue the transmission defects in H
cNMJs that lack NCAM. Indeed, when we introduced a
peptide that we designed to interact with MLCK, induc- p
uing a conformation to make MLCK constitutively activeFigure 4. The Effect of Peptides that Inhibit
or Make MLCK Constitutively Active on
Transmission at Wild-Type P30 and NCAM
180 Null NMJs
(A) The MLCK inhibitory peptide at a bath
concentration of 3 M was introduced into a
wild-type NMJ that was then stimulated at
10, 20, 50, and 100 Hz. The EPP traces show
that transmission failures were apparent at
20 Hz and became more pronounced at
higher stimulation frequencies.
(B) The number of failures in a 0.5 s train at
each of these frequencies is quantified for
multiple junctions (n = 12).
(C) Bar graphs showing quantal content,
MEPP frequency, MEPP amplitude, and de-
pression (expressed as the ratio of the mean
EPP amplitude of the first five to the last five
stimuli in a 1 s train) in control wild-type,
wild-type with MLCK inhibitory peptide, and
NCAM 180 null NMJs with the MLCK ago-
nist peptide.
(D) Introduction of the MLCK agonist peptide
into a NCAM 180 null NMJ at a bath concen-
tration of 3 M rescued the transmission fail-
ures when stimulus trains of 10, 20, 50, and
100 Hz were applied for 0.5 s.
(E) (Top) Bar graphs quantifying the level of
myosin light chain phosphorylation via the
ratio of immunostaining with an antibody
that recognizes MLC when it is phosphory-
lated at threonine 18/serine 19 over immuno-
staining with a pan MLC antibody in PC12
cell lysates, made from PC12 cells that were
either untreated or assayed 5 min following
an exposure to 55 mM KCl for 1 min or assayed following the introduction of the MLCK agonist peptide with or without KCl-mediated
depolarization (the latter two treatments resulted in a significant increase in phosphorylated MLC versus the control; p < 0.05). (Bottom) A
representative Western blot showing the bands for phosphorylated MLC, all MLC, and actin as a loading control under these same conditions.
Quantification of data is expressed as the mean ± SEM.see Experimental Procedures) into NCAM null (data not
hown) or 180 isoform null NMJs (Figure 4D), the trans-
ission failures observed at high stimulus rates were
ompletely prevented. To ensure that our designed
eptide constitutively activated MLCK, we tested its
bility to lead to phosphorylation of myosin light chain
MLC) in the absence of stimulation.
To obtain sufficient material for biochemical analysis,
e used cultures of PC12 cells that had been stim-
lated to differentiate into a neuronal form. These cells
ere either not stimulated or stimulated with exposure
o high K+ (55 mM) for 1 min. Following stimulation,
LCK-mediated phosphorylation of serine 19 and thre-
nine 18 on MLC is generally considered to peak within
econds and to then decline toward baseline within
inutes (Somlyo and Somlyo, 2003). We therefore per-
ormed Western blots of the PC12 cell lysates at 5 min
fter stimulation using an antibody that specifically rec-
gnizes serine 19 and threonine 18 on MLC when they
re phosphorylated. Figure 4E shows that there is a
aseline level of phosphorylation that occurs even in
he unstimulated cells (lane 1). Five minutes following
he 55 mM K+ stimulation, phosphorylation was still
omewhat increased over the baseline values (lane 2).
owever, introduction of the peptide to make MLCK
onstitutively active resulted in a 3-fold increase in
hosphorylation in both the unstimulated and stim-
lated cells (lanes 3 and 4, respectively). There was no
NCAM Signaling and Transmission
923change in the level of MLC, visualized with a pan-MLC
antibody that recognizes both phosphorylated and
nonphosphorylated states, nor in the level of actin used
as a loading control. In summary, the peptide that we
have designed does appear to make MLCK constitu-
tively active, even in the absence of stimulation and
Ca2+/calmodulin activation. The fact that this peptide
rescued the transmission failures in NCAM 180 null
NMJs strongly suggests that inadequate activation of
MLCK occurs in the absence of the 180 isoform of
NCAM and that this underlies the transmission failures.
The data presented thus far indicate that MLCK is an
important link in the pathway by which the KENESKA
peptide, and by inference this domain on NCAM, allows
mouse NMJs to maintain a high level of transmitter out-
put, even when challenged by high-frequency stimula-
tion. Although MLCK may have other targets, its most
generally accepted role is in the activation of myosin
light chain via phosphorylation of serine 19 and to a
lesser extent threonine 18. This in turn stimulates actin
binding and filament formation by myosin II heavy
chain, which increases the MHC ATPase activity neces-
sary for force generation (Somlyo and Somlyo, 2003).
Figure 5A illustrates the major pathways known to regu-
late phosphorylation of serine 19 and threonine 18 in
other systems and shows that its activation is a bal-
ance between phosphorylation by MLCK and dephos-
phorylation by myosin light chain phosphatase (MLC-P)
(Isotani et al., 2004; see Brown and Bridgman, 2003,
Somlyo and Somlyo, 2003, and Riento and Ridley, 2003,
for reviews). Many signal transduction pathways can
affect both MLCK and MLC-P activity, including PKA,
PKC, Ca2+-CaM, and Rho kinases. Various studies have
provided evidence for a role of several myosins, such
as myosin IIA, IIB, and V, in the movement of vesicles
and in secretion (Rose et al., 2003; Neco et al., 2004;
Libby et al., 2004), although the cellular mechanisms
are not well understood and their roles may differ with
cell type. We have previously demonstrated that MLCK
is highly expressed at wild-type, NCAM null, and NCAMFigure 5. Major Pathways by which the
KENESKA Domain of NCAM May Affect
Transmission by Altering MLCK and MLC
Activation
(A) Diagram showing that the major target of
MLCK is its phosphorylation of MLC at ser-
ine 19/threonine 18. The level of phosphory-
lation at this site depends on the balance of
MLC kinase and MLC phosphatase. Rho ki-
nase, PKC, and PKA can also potentially
modulate this pathway. Outlined in bold are
the molecules that our data support as being
in the pathway required for sustained trans-
mission at high stimulus frequencies.
(B) Immunostaining of wild-type NMJs show
that myosin IIA, myosin IIB, and myosin Va
are all present at P30 wild-type endplates
(right panels), visualized by the α-BTX stain-
ing (left panels). Immunostaining for these
myosins also occurred to some extent along
preterminal axons (see, for example, that of
myosin IIB). Calibration bar, 40 M.
Quantification of data is expressed as the
mean ± SEM.180 null NMJs (Polo-Parada et al., 2004). Figure 5B
shows that mouse NMJs also express myosin IIA, myo-
sin IIB, and myosin Va. In the experiments described
below, we have attempted to use peptide and other
specific inhibitors, alone or in combination, to begin to
elucidate the pathways underlying the transmission
failures that result from the lack of the 180 isoform of
NCAM.
The KENESKA Peptide Appears to Be Mediating
Effects on Transmission Primarily through
Its Effect on MLCK
If the lack of NCAM or the 180 isoform of NCAM is pro-
ducing transmission failures solely because of the in-
ability of the KENESKA domain of the 180 kDa isoform
of NCAM to interact with other presynaptic proteins,
one would predict that introduction of this peptide into
the NCAM mutant junctions should not produce effects
on transmission additive to those brought about by the
absence of the NCAM 180 itself. As shown in Figure 6A,
introduction of the peptide into the NCAM 180 null
NMJs did not produce additional failures in transmis-
sion compared to the mutant phenotype. Similar results
were found when KENESKA was introduced into the
total NCAM null NMJ (data not shown). Introduction of
the phosphorylated KENESKA peptide also did not pro-
duce additional transmission failures.
Similar reasoning would suggest that, if the KEN
ESKA peptide is producing its effect on transmission
solely by preventing the full activation of MLCK, making
MLCK constitutively active should abrogate the trans-
mission failures produced by the introduction of the
KENESKA peptide. Indeed, when the MLCK agonist
peptide was introduced into a wild-type NMJ 30 min
prior to introduction of the KENESKA peptide, no trans-
mission failures were produced (Figure 6B). To ensure
that the KENESKA peptide, when applied sequentially
after application of the MLCK agonist peptide, was ac-
tually entering the cell, the following control experiment
was performed. The KENEGA peptide, which had pro-
Neuron
924Figure 6. Effects of the KENESKA Peptide on
NCAM 180 Null NMJs and on Wild-Type
NMJs in which MLCK Has Been Made Con-
stitutively Active
(A) (Top) Traces showing an example of EPPs
in response to a 100 Hz train in a 180 null
NMJ (top trace) and a 180 null NMJ into
which the KENESKA peptide was introduced
(bottom trace). (Middle) Bar graphs showing
that introduction of the KENESKA peptide
into 180 null NMJs (black bars) does not alter
quantal content, MEPP amplitude, MEPP
frequency, or depression, compared to un-
treated NCAM 180 null NMJs. (Bottom) The
number of failures within 1 s trains of stimuli
for NCAM 180 null NMJs (white bars) and
180 null NMJs treated with the KENESKA
peptide (black bars) did not differ signifi-
cantly (p < 0.05) for 10, 20, 50, 100, or 200
Hz stimulation.
(B) No effects on transmission are produced
by the KENESKA peptide when introduced
into wild-type NMJs in which the MLCK ago-
nist peptide had been introduced 30 min be-
fore. (Top) Examples of EPPs during 0.5 s
trains at 10, 20, 50, 100, and 200 Hz. (Bot-
tom) Bar graphs showing the effect of this
dual treatment (black bars) on quantal con-
tent, MEPP amplitude, MEPP frequency, and
depression compared to wild-type NMJs
(white bars).duced no failures when applied alone, was applied first. T
MAs expected, no failures were produced, but the subse-
quent application of the KENESKA peptide resulted in o
A45 ± 11 (n = 7) failures during a 100 Hz train, which was
not significantly different from 38 ± 5 failures that had t
sbeen found previously when KENESKA was applied
alone. Taken together these observations provide evi- b
sdence that the effect of the KENESKA peptide, and thus
we infer of this domain of NCAM, in preventing trans- N
dmission failures with high-frequency repetitive stimula-
tion, is mediated primarily through MLCK. hhe Effects of MLCK on Transmission May Be
ediated by Its Phosphorylation
f Myosin Light Chain
s noted earlier, MLCK regulates MLC via phosphoryla-
ion of serine 19/threonine 18. Figure 7A (top left pair)
hows that an antibody that recognizes MLC when
oth of these residues are phosphorylated causes
trong punctate immunostaining in control wild-type
MJs. Furthermore, such immunostaining was greatly
ecreased in NMJs into which the KENESKA peptide
ad been introduced 1 hr before (top right pair). Quan-
NCAM Signaling and Transmission
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Stimulation
(A) Immunostaining of P30 NMJs with an antibody that recognizes MLC only when serine 19 and threonine 18 are phosphorylated shows
bright punctate staining at endplates visualized by α-Btx (top left pair). Introduction of the KENESKA peptide greatly reduced this staining
(top right pair). In contrast, introduction of the MLCK agonist peptide greatly increased the immunostaining at the endplate (middle left pair).
Prior introduction of the MLCK agonist peptide prevented the reduction in immunostaining caused by the KENESKA peptide (middle right
pair). The MLC inhibitor peptide (bottom left pair) and the Rho kinase inhibitor Y2362 (bottom right pair) also reduced immunostaining for
phospho-MLC. Bar graph at far right shows quantification of immunostaining of different peptides/inhibitors when applied alone or in combi-
nation (see Experimental Procedures and Polo-Parada et al., 2004, for details).
(B) Introduction of a MLC inhibitory peptide produced transmission failures in a P30 NMJ stimulated at 200 Hz.
(C) Bar graph showing the number of failures/s during a 100 Hz train for the MLC inhibitor peptide and the Rho kinase inhibitor Y2362 at 100
M at wild-type NMJs compared to the failures in the NCAM 180 null NMJs and the phosphatase inhibitor microcystin-LR at 10 M at 180
null NMJs.
Quantification of data is expressed as the mean ± SEM.tification of the phospho-MLC immunostaining (bar
graph, right) showed that the reduction in immuno-
staining was statistically significant. Phospho-MLC
levels were also reduced by the MLCK inhibitory pep-
tide (bar graph, right). In contrast, introduction of the
peptide, which was demonstrated to make MLCK con-stitutively active in PC12 cells (Figure 4E), caused a
large increase in phospho-MLC in the endplate (Figure
7A, middle left pair and bar graph). It also increased
phospho-MLC immunostaining in muscle fibers and in
smooth muscle of intramuscular blood vessels (data
not shown). Finally, introduction of the KENESKA pep-
Neuron
926tide into NMJs in which MLCK had been made constitu- w
otively active did not reduce immunostaining for phos-
pho-MLC (middle right pair and bar graph). Taken c
atogether, the observations obtained with the phospho-
specific MLC antibody provide evidence that the KEN o
mESKA peptide results in alterations in the level of ser-
ine19/threonine 18 phosphorylation that are consistent s
twith the proposed role of this domain of NCAM in syn-
aptic transmission. s
1Additional evidence that failure of this site on MLC to
be phosphorylated leads to transmission failures was t
Kobtained by introducing a peptide (MLC inhibitory pep-
tide, see Experimental Procedures) that mimics this site w
uand that should therefore compete for phosphorylation
of this site on MLC by MLCK and thus prevent or re- m
tduce its phosphorylation. Failures in transmission at
high frequencies, at the approximate level of those w
ecaused by phospho-KENESKA, were in fact produced
when this peptide was introduced into wild-type NMJs e
n(Figures 7B and 7C), while other parameters of trans-
mission, including MEPP amplitude, frequency, and t
pquantal content to single stimuli, were not altered (data
not shown). This peptide also reduced the level of a
aimmunostaining for phospho-MLC (Figure 7A, bottom
left pair and bar graph). a
sIn other systems, Rho kinase has been shown to indi-
rectly result in phosphorylation of MLC. While this can
voccur via several routes (see Figure 5), the most gen-
perally accepted one is by Rho kinase inhibiting MLC-P,
iwhich in turn results in higher levels of MLC phosphory-
tlation (Isotani et al., 2004; Somlyo and Somlyo, 2003;
tRiento and Ridley, 2003). Furthermore, it has been re-
fported that the 180 but not the 140 cytoplsmic domain
pof NCAM, when used in affinity column chromatogra-
dphy, is able to pull down Rho kinase (Buttner et al.,
t2003). The Rho kinase inhibitor Y-27632, which strongly
pinhibits phosphorylation of this site in retinal ganglion
icells (Wahl et al., 2000), produced transmission failures
aat +/+ NMJs at high stimulus frequencies (Figure 7C) as
twell as decreased phosphorylation of MLC detected by
cimmunostaining (Figure 7A, bottom right pair), demon-
nstrating that Rho kinase can modulate the MLCK-MLC
apathway at the NMJ. Microcystin-LR, a phosphatase
minhibitor that will inhibit MLC-P (and possibly other
pphosphatases), prevented the failures in the NCAM 180
inull NMJ. This result is consistent with an adequate
Tlevel of MLC phosphorylation, which is a balance be-
stween phosphorylation by MLCK and dephosphoryla-
ition by MLC-P, as being a critical variable for maintain-
ting adequate transmission. However, inhibition of Rho
wkinase must affect a pathway in addition to the KEN
pESKA-MLCK-MLC pathway, since application of both
ithe KENESKA peptide and the Rho kinase inhibitor
sY-27632 (Figure 7, bar graph) produced a number of
tfailures that was approximately the sum of that pro-
fduced by Y-27632 (Figure 7, bar graph) or KENESKA
l(Figure 3B, left) alone.
oIn summary, these data make a strong case for a
pathway in which the KENESKA domain of NCAM me-
Ddiates the activation of MLCK. This in turn regulates
MLC, which is required for effective transmission at
high stimulus rates. We speculate that one of the non- P
fmuscle myosins is the downstream target of this path-ay and that it may act either by facilitating the delivery
f vesicles to active zones or their subsequent exo-
ytosis. Since myosin IIA and IIB are regulated by MLC
nd are present presynaptically, we assessed the effect
f blebbistatin, which specifically inhibits nonmuscle
yosin IIA and IIB, but not myosin Va, myosin X, or
mooth muscle myosin II (Straight et al., 2003). Applica-
ion of 100 M blebbistatin produced approximately the
ame number and pattern of transmission failures at
00 Hz (Figure 8A) as had the phospho-KENESKA pep-
ide (Figure 3B). This suggests that the effects of the
ENESKA peptide are likely mediated by interfering
ith a myosin II-mediated process. The rescue of fail-
res in the 180 null NMJ by the phosphatase inhibitor
icrocystin-LR also appears to be via myosin II, since
he failures produced by blebbistatin in wild-type NMJs
ere not rescued by microcystin-LR (Figure 8B). How-
ver, when blebbistatin-treated NMJs were exposed to
ither the phospho-KENESKA peptide or the Rho ki-
ase inhibitor, additional failures were produced. While
he number of failures was less than the sum of those
roduced by blebblistatin and either of these agents
lone, these results suggest that both the KENESKA
nd Rho kinase signaling pathways are likely to affect
process involved in maintaining effective transmis-
ion in addition to that mediated by mysosin II.
While the effects on transmission produced by the
arious peptides appeared to be presynaptic, bath ap-
lication of the peptide-carrier complex should result
n peptides entering both the presynaptic terminal and
he muscle fiber. Thus we cannot exclude that some of
he peptides produced presynaptic effects indirectly by
irst acting on muscle or Schwann cells (see, for exam-
le, Micheva et al., 2003). To provide more direct evi-
ence for the site of action, a micropipette containing
he phospho-KENESKA peptide-Chariot complex was
ositioned close to an endplate, based on the record-
ng of extracellular synaptic currents (Polo-Parada et
l., 2001). Applying current pulses for 30 min to eject
he peptide-carrier complex (see Experimental Pro-
edures) was sufficient to cause failures with 100 Hz
erve stimulation (Figure 8C), confirming that we were
ble to eject a sufficient amount of peptide by this
ethod to cause a response. When the same delivery
rotocol was used to eject peptide synaptically after
mpaling a muscle fiber, no failures were produced.
aken together, this evidence indicates a presynaptic
ite of action for the phospho-KENESKA peptide. The
mmunostaining for phospho-MLC (Figure 7A), which
he various applied peptides altered in ways consistent
ith their effects on transmission, also appeared to be
resynaptic; the punctate staining along the axon and
n the terminal was above the focal plane of the post-
ynaptic ACh receptors visualized by fluorescently
agged α-BTX and was in fact localized in the same
ocal plane as presynaptic vesicle markers. Thus it is
ikely that most of the effects of the peptides we have
bserved result from a presynaptic site of action.
iscussion
revious studies from this laboratory discovered a role
or NCAM, specifically its 180 kDa isoform, in maintain-
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Those Caused by Phospho-KENESKA Are
Produced by the Myosin II Inhibitor Blebbi-
statin and a Presynaptic Site of Action Is In-
dicated for the Phospho-KENESKA Peptide
(A) Trains of EPPs at 100 Hz stimulation from
the same cell prior to (top trace) and after
(bottom trace) the application of 100 M
blebbistatin (recordings were made from su-
perficial fibers, as blebbistain did not pene-
trate well into the muscle).
(B) Bar graph showing the number of fail-
ures/100 Hz train with blebbistatin alone or
when blebbistatin was combined with either
phospho-KENESKA, the phosphatase inhibi-
tor Microcystin-LR (10 M), or the Rho ki-
nase inhibitor Y-27623 (100 M).
(C) Extracellular iontophoresis of the phos-
pho-KENESKA peptide resulted in failures
during 100 Hz nerve stimulation; top trace,
extracellular recording of synaptic current at
start of train, showing stimulus artifact (1),
presynaptic current (2 and 3), and postsyn-
aptic current from EPP (4); bottom trace, a
response from within the train where the
postsynaptic response was missing. Bar
graph, mean number of failures/100 Hz train.
(D) 100 Hz train of EPPs recorded postsyn-
aptically from a muscle fiber before and after
iontophoresis of the phospho-KENESKA pep-
tide into the muscle fiber at the synaptic site.
No failures occurred.ing effective neuromuscular transmission with repeti-
tive stimulation (Polo-Parada et al., 2001; Polo-Parada
et al., 2004). We have now identified a highly conserved
intracellular domain on NCAM that mediates these ef-
fects, and we provide substantial evidence that it acts
by allowing sufficient MLCK activation; this in turn we
speculate is required for myosin II-driven movements
needed to replenish synaptic vesicles used during
high-frequency stimulation. Introduction of the KEN
ESKA peptide, which corresponds to the C-terminal
portion of this conserved domain, into adult +/+ mouse
NMJs produced transmission failures similar to those
seen in the NCAM 180 null mouse. In contrast, this pep-
tide had no effect on transmission in NMJs that lacked
the 180 kDa NCAM isoform. The ability of NCAM to act
as a signaling molecule has been increasingly appreci-
ated (Crossin and Krushel, 2000; Hinsby et al., 2004),
and the domain and pathway we describe here add to
the expanding list of NCAM-mediated signaling path-
ways. In addition, since these effects were caused by
acute application of the peptide in adult +/+ NMJs, the
transmission defects seen in the 180 null mouse are
unlikely to have resulted from developmental alter-
ations caused by NCAM’s absence; instead, our data
point to the 180 isoform of NCAM as playing an essen-
tial role in adult neuromuscular transmission.
To elucidate the potential role of the KENESKA do-
main of NCAM in maintaining effective high-frequency
transmission, we introduced this and other peptides di-
rectly into adult NMJs in acutely isolated muscles. We
propose that the KENESKA peptide produced failures
at +/+ NMJs by preventing this domain on synapticallylocalized 180 kDa NCAM from binding/interacting with
other intracellular molecules required for the down-
stream activation of MLCK. The fact that the KENESKA
peptide was without effect in NCAM 180 null NMJs and
that a scrambled peptide or one in which the serine
had been replaced with glycine was also without effect
pointed to the specificity of these interactions and
the importance of serine phosphorylation in regulating
these effects of NCAM. The latter conclusion was
strengthened by the fact that introduction of the serine
phosphorylated KENESKA or one in which serine was
replaced by an aspartate, mimicking a phosphorylated
amino acid at this site, produced even more abundant
transmission failures, closely approximating the 180
null phenotype. We suggest that the binding of this do-
main to an intracellular PDZ-like binding partner is reg-
ulated by phosphorylation of this serine.
Although both the 140 and 180 isoforms of NCAM
possess the KENESKA domain, the 140 isoform was
unable to compensate for the absence of the 180 iso-
form in preventing transmission failures. This could re-
sult if the 180 and 140 isoforms are located in different
microdomains at the synapse, since the signaling
pathways utilized by NCAM isoforms can depend on
whether they are localized within lipid rafts (Nietham-
mer et al., 2002). We have previously shown that the
180 isoform is localized presynaptically in a punctate
pattern (Polo-Parada et al., 2004), but unfortunately, no
antibody exists that allows one to determine the loca-
tion of the 140 isoform. Alternatively, the KENESKA do-
main on the 140 isoform might be effectively masked,
but the insertion of the alternatively spliced 180 unique
Neuron
928domain might allow the KENESKA domain to more ef- 1
fectively interact with its putative binding partners. In o
addition, a different localization of the 180 isoform a
might facilitate the phosphorylation of the serine within p
the KENESKA domain that would in turn mediate spe- t
cific interactions of this isoform. o
The transmission defects that have been described b
appear to be entirely presynaptic (Polo-Parada et al., m
2001; Polo-Parada et al., 2004), and the effects of the z
peptides we have introduced are most likely explained t
by their acting presynaptically. We have not yet iden- o
tified the protein that directly interacts with the KEN a
ESKA domain; however, the results of introducing pep- n
tides that either activated or inhibited MLCK alone or
in combination with the KENESKA peptide clearly place N
this kinase at a critical position in the signaling pathway E
of the NCAM 180 isoform which prevents transmission d
failures. These observations confirm and extend sev- m
eral other studies showing the importance of MLCK o
in maintaining synaptic transmission in hippocampal t
(Ryan 1999) and sympathetic (Mochida et al., 1994; g
Mochida, 1995) neurons. The current study has also f
provided direct evidence that the KENESKA peptide w
and those that either inhibit or make MLCK constitu- p
tively active altered the phosphorylation of threonine18/ r
serine 19 on MLC within in vivo NMJs in a manner con- t
sistent with MLCK’s proposed role in transmission. This w
site on MLC is a main target of MLCK (Kamm and Stull c
2001) that regulates the activation of myosins in smooth t
muscle, motile cells, neuronal growth cones, and secre- c
tory cells (Matsumura et al., 1998; Schmidt et al., 2002; d
Somlyo and Somlyo, 2003; Neco et al., 2004).
While we cannot be certain that the observed m
changes in phosphorylation of this site on MLC were t
responsible for the alterations in transmission pro- d
duced by the various peptides alone or in combination, a
the data clearly indicate that introduction of the KEN q
ESKA peptide was able to bring about a biochemical w
change in MLC at this site consistent with the effects o
we observed on transmission. Taken together our data T
suggest that the ultimate downstream target of the i
KENESKA domain of NCAM in mediating effective t
transmission is likely to be one of the nonmuscle myo- m
sins, which have been implicated in either vesicle
i
movement or synaptic transmission. Myosin Va, which
p
we have shown is present at mouse NMJs, has been
sshown in several systems to couple synaptic vesicles
pwith either actin filaments or microtubules and thus
plays a role in their transport (Evans et al., 1998; Brown
Eet al., 2003; Cao et al., 2004). However, hippocampal
synapses of a mouse mutant for myosin Va exhibited M
normal transmission and plasticity (Schnell and Nicoll, N
2001, but see Libby et al., 2004). In addition, our data d
on the effects of blebbistatin support instead a role for g
dmyosin II at mouse NMJs.
(Myosin II is required to maintain normal transmission
at sympathetic ganglion synapses (Mochida et al.,
E1994; Mochida, 1995) and for both the movement and
Ssubsequent exocytosis of vesicles in chromaffin cells
f(Neco et al., 2004; but see Rose et al., 2003). Our data,
p
showing a pathway involving MLC, would be most con- T
sistent with a role for myosin II, where regulation by T
MLC is generally accepted. It would also fit nicely with m
ωstudies by Mochida (Mochida et al., 1994; Mochida,995), which showed that interfering with the function
f presynaptic myosin II at sympathetic ganglionic syn-
pses produced a decline in transmission that was de-
endent on the synapses being activated. The fact that
he decline in transmission depended on the pattern
f stimulation and that the induction of PTP was also
locked led the authors to propose that myosin II was
ost likely involved in supplying vesicles to the active
one to replenish those released and thus was required
o maintain transmission with repetitive stimulation. In
ur study as well, transmission failures only occurred
t higher frequencies of stimulation and following a
umber of EPPs of normal amplitude.
The cycles of total transmission failures in both
CAM 180 null NMJs and +/+ NMJs treated with KEN
SKA peptides are unusual in that they imply an un-
erlying process with some threshold that results in
ultiple release sites releasing either a normal amount
f transmitter or none at all. This might occur if some
hreshold level of kinase activation was needed to en-
age a signaling pathway required to mobilize vesicles
rom the reserve pool. In its absence, no release sites
ould be replenished with synaptic vesicles. Some
eriod of time, in the absence of exocytosis, might be
equired for this process to recover. Finally, it is clear
hat failures of exocytosis occur, but the extent to
hich alterations in either fast or slow forms of endo-
ytic vesicle cycling (Virmani et al., 2003) contribute to
he phenotype will require extensive characterization of
ycling kinetics using styryl dyes, which is currently un-
erway.
In summary, while more work will be needed to deter-
ine which myosins (myosin IIA or IIB) are involved in
ransmission at adult mouse NMJ as well as to eluci-
ate their precise roles in synaptic vesicle movement
nd exocytosis required to maintain effective high-fre-
uency transmission, it seems very likely that the path-
ay we have described involving the KENESKA domain
f the 180 isoform of NCAM will play an essential role.
he present study has also shown that it is possible to
ntroduce peptides via a peptide carrier into the junc-
ions of adult, acutely isolated muscles and that this
ethod can be used to probe specific protein-protein
nteractions, including those regulated by the phos-
horylation state of the protein. Such an approach
hould be widely useful in other isolated organ/tissue
reparations.
xperimental Procedures
ice
camtm1cwr mice were generated by H. Tomasiewicz, as previously
escribed (Polo-Parada et al., 2004). Wilde-type (+/+) and homozy-
ous 180 knockout mice were identified by PCR using primers that
istinguish wild-type from mutant alleles as described previously
Polo-Parada et al., 2001; Polo-Parada et al., 2004).
lectrical Recordings
tandard electrophysiological procedures were used to record
rom P30 acutely isolated semitendinosus muscles as described
reviously (Polo-Parada et al., 2001 and Polo-Parada et al., 2004).
he semitendinosus muscle preparation was perfused with normal
yrode’s solution (125 mM NaCl, 5.37 mM KCl, 24 mM NaHCO3, 1
M MgCl2, 1.8 mM CaCl2, and 5% dextrose, containing 1 M
-conotoxin GIIIB) (Alomone Labs, Jerusalem, Israel), which spe-
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contraction. Sharp glass electrodes were pulled (20–40 M), filled
with 3 M KCl, and single muscle fibers were impaled near the motor
endplate. Potentials were recorded via intracellular amplifier (World
Precision Instruments) using Axoscope software (40 KHz sampling
rate; Axon Instruments, Union City, CA). The nerves were sucked
into tight polyethylene-stimulating electrodes pulled from polyeth-
ylene tubing (PE-190; Clay Adams, Parsippany, NJ) and stimulated
with a Grass SW38 stimulator thorough a PSIU6B isolation unit
(Grass Instruments, Quincy, MA).
Perineural Recordings
Appropriate positioning of sharp electrodes close to the terminal
allows electrotonically conducted currents from the nerve terminal
to be recorded as voltage drops across the perinerium as pre-
viously described in detail (Brigant and Mallart, 1982; Urbano et al.,
2002; Polo-Parada et al., 2004). Statitistical analyses were per-
formed using Student’s t test in Sigma plot 2.0.
Introduction of Peptides into Adult NMJs
Peptides were introduced into the semitendinosus NMJ-muscle
preparation by using the Chariot protein method (Active Motif,
Carlsbad, CA). Briefly a Chariot stock solution was prepared by
diluting 1.2 mg of Chariot reagent in 600 l ddH2O and preserved
at −70°C. The Chariot stock solution was further diluted to a final
concentration of 2 g in 100 l of normal Tyrode’s solution and
sonicated in a water bath for 30 min. The peptides were prepared
as a stock solution of 50 M in ddH2O and preserved at −70°C. An
aliquot of 10 l stock peptide solution was defrosted and further
diluted to a final concentration of 15 M in 100 l of normal Ty-
rode’s solution and sonicated for 30 min in a water bath. These two
solutions were mixed, vortexed, and sonicated in a water bath for
1 hr to allow the Chariot-peptide complex to form. The Chariot/
peptide complex mixture was then diluted to a final volume of 1 ml
with normal Tyrode’s solution, (final peptide concentrationw3 M)
and bubbled with 95%O2/5% CO2. The semitendinosus prepara-
tion was incubated in this mixture for 1 hr and then washed five
times with normal Tyrode’s solution and incubated for an additional
1 hr in the presence of oxygenated Tyrode’s solution with 95%O2/
5%CO2 containing 1 M ω-conotoxin GIIIB. Then the preparation
was washed five times with normal Tyrode’s solution and continu-
ously perfused with freshly oxygenated Tyrode’s solution (0.2 ml/
min) during recordings. To distinguish whether the phospho-KEN
ESKA peptide was acting pre- or postsynaptically, a 50× Chariot-
phospho-KENESKA complex was prepared as described above
and diluted in 1 ml of 3 M KCl. Sharp electrodes were backfilled
with this solution, and endplates were located by extracellularly
recorded EPPs (see Polo-Parada et al., 2001). 5 ms pulses of 10 nA
current were then injected into the pipette at a frequency of 10 Hz
for 30 min to iontophorese the peptide complex onto the synaptic
terminal. Following a 1 hr wash, the nerve was stimulated at 100
Hz, and the number of failures was determined by the loss of the
postsynaptic component of the extracellular current recordings
(see Polo-Parada et al., 2001). In other preparations, after detection
of the extracellular EPP, the muscle fiber was impaled, the same
protocol used to eject the phospho-KENESKA peptide, and the
number of transmission failures determined.
Peptides used were as follows: the series used to probe the
C-terminal domain of NCAM were KENESKA, KENE[p-Ser]KA,
KENEGKA, KENEDKA, and CSNKATAETKQE. The MLCK-inhibitory
peptide used is an 11-residue synthetic peptide analog, corre-
sponding to part of the calmodulin binding sequence in skeletal
muscle myosin light chain kinase. This peptide, LRRWLLNFIAV
(Sigma, Saint Louis, MO), inhibited calmodulin-dependent activa-
tion of the smooth muscle myosin light chain kinase (Kemp et al.,
1987). The MLCK agonist peptide sequence was SKDRMKKYMA
(from the 788 to 796 aa of the inhibitory domain of MLCK; Tanaka
et al., 1995). The MLC inhibitory peptide had the sequence
KQAQRGSSNVFSM and was derived from sequences flanking the
serine 19/threonine 18 on MLC (Swiss Prot |Q9QVP4|MLRA_Mouse)
that are phosphorylated by MLCK and mimic the MLC-substrate.
The peptides were 95% pure and synthesized by the Analysis
Dept., Wolfson Institute for Biomedical Research, London.Immunostaining
P30 mice were sacrificed in CO2 chamber, and semitendinosus
muscles were quickly removed and fixed in 3.7% formaldehyde,
5% sucrose in PBS and cryoprotected in 30% sucrose overnight.
Frozen sections (30 M) were cut, air-dried, and stored at −70°C.
All stainings were performed by blocking the sections with 2% BSA
in PBS and incubation with the appropriate primary antibodies at
4°C for 24 hr, followed by incubations with fluorochorome-conju-
gated secondary antibodies (Zymed, San Francisco, CA). Primary
antibodies used were pMLC2 (T18/S19), from Cell Signaling Tech-
nology (Beverly, MA), and myosin IIA, IIB, and Va from Sigma (St.
Louis, MO). Pictures were acquired and processed with an Olym-
pus Magnifier CCD camera or a Olympus 2000 camera (Olympus,
America) and Adobe Photoshop 8.0, respectively. Quantification of
immunostaining was as described in Polo-Parada et al., 2004.
SDS-PAGE Immunobloting
PC12 cells were grown to 95% confluence in DMEM + 10% FBS in
a 10% CO2 incubator. PC12 cells were exposed to 55 mM KCl for
1 min, washed five times with standard Tyrode’s solution, and after
a 5 min delay, lysates were prepared from unstimulated or K+-stim-
ulated cultures. In two additional sister cultures, the Chariot
method was used to introduce the caMLCK peptide into the cells
as described previously. One culture was unstimulated while the
other was exposed to the same KCl protocol previously described.
Cells were homogenized in HEPES extraction buffer (25 mM
HEPES, 150 mM NaCl, 1 mM EDTA) containing 1% NP-40 and pro-
tease inhibitor mixture (Roche Diagnostics, Manheim, Germany).
The solubilized protein concentration was determined (BCA
method; Pierce, Rockford, IL) and adjusted to 1 g/ml. SDS sample
buffer containing dithiotheritol was added to each sample, and the
proteins were separated by SDS-page according to the Laemmli
method on a 20% gel. The proteins were transferred onto polyvinyl-
idene fluoride membranes, which were immunostained with a
phospho-myosin light chain (Thr18/Ser19) antibody (Cell Signaling,
Beverly MA) and appropriate HRP-conjugated secondary antibody,
which was visualized with a chemiluminescence kit (ECL, Pierce).
Quantification of the MLC band was performed using the Versidoc
gel quantification system.
Bioinformatics
Conserved regions within the intracellular domain of NCAM 180
(SWISS PROT|P13595|NCA1_MOUSE) were detected with the se-
quence alignment program ClustalW (Thompson et al., 1994). Con-
served sequences were searched for homologies with P-Blast
(Altschuh et al., 1997). Secondary structure was predicted using
the software PHDsec (Rost and Sander, 2000), and potential phos-
phorylation sites were detected using NetPhos (Blom et al., 1999).
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